Results of the PCaI prostate cancer patient “value” survey

Earlier this year, in late May and early June, Prostate Cancer International (PCaI) conducted what we have described as a very primitive pilot survey on prostate cancer patients’ perceptions of “value” in the management of this disease. … READ MORE …

Communication and value in the management of prostate cancer

When your sitemaster speaks to the assembled audience  at the annual meeting of ASTRO this coming Sunday, one point he intends to make relates to the importance and value of clear, straightforward, high-quality communication between physicians and patients. … READ MORE …

Yet another new type of HIFU is now in Phase II clinical trials

Another breathless media release has announced enrollment of the first patient into a Phase II clinical trial of yet another new form of high-intensity, focused ultrasound (HIFU) in men with low-risk and favorable, intermediate-risk, localized prostate cancer. … READ MORE …

After long-term ADT … recovery of normal hormonal function?

A group of Spanish clinical researchers have reported recent data from a small study designed to address an unanswered question about the recovery of (relatively) normal hormonal function after completion of androgen deprivation therapy (ADT). … READ MORE …

Very early salvage radiation has up to fourfold better outcomes and saves lives

Another subject that has come up a lot recently is when to have salvage radiation. It is always a pressing decision for those 30 percent of prostatectomy patients who have detectable PSA after prostatectomy. … READ MORE …

Hypofractionated radiation therapy using IMRT has a clear advantage

I was reticent to write about hypofractionation yet again after writing about it so often in the last year (see this link for my latest summary). … READ MORE …

Formal comment from ASTRO on the results of the ProtecT trial

The following official statement was issued on September 15 by the American Society for Radiation Oncology (ASTRO): … READ MORE …